YU37299A - Karbapenemsko jedinjenje, njegova primena i njegovo intermedijarno jedinjenje - Google Patents

Karbapenemsko jedinjenje, njegova primena i njegovo intermedijarno jedinjenje

Info

Publication number
YU37299A
YU37299A YU37299A YU37299A YU37299A YU 37299 A YU37299 A YU 37299A YU 37299 A YU37299 A YU 37299A YU 37299 A YU37299 A YU 37299A YU 37299 A YU37299 A YU 37299A
Authority
YU
Yugoslavia
Prior art keywords
infection
preventives
remedies
compound
pharmaceutically acceptable
Prior art date
Application number
YU37299A
Other languages
English (en)
Inventor
Hiroshi Matsui
Masayasu Kasai
Original Assignee
Kyoto Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto Pharmaceutical Industries Ltd. filed Critical Kyoto Pharmaceutical Industries Ltd.
Publication of YU37299A publication Critical patent/YU37299A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Karbapenemsko jedinjenje formule (I): gde svaki simbol je kao sto je definisano u specifikaciji, i njegova farmaceutski prihvatljiva so. Karbapenemsko jedinjenje (I) i njegova farmaceutski prihvatljiva so predmetnog pronalaska pokazuju izvanrednu absorpciju iz digestivnog trakta pri oralnoj primeni, i dovoljnu antibakterijsku aktivnost protiv sirokog varijeteta bakterijskih vrsta. Tako, ovi su krajnje primenljivi kao agensi za profilaksu i tretiranje infektivnih obolenja, narocito bakterijskih infektivnih obolenja. Pomenuti agensi za profilaksu i tretiranje infektivnih obolenja. Pomenuti agensi za profilaksu i tretiranje infektivnih obolenja mogu da budu korisceni kao agensi za profilaksu i tretiranje obolenja koja su izazvana pomocu bakterija (na primer, gnojna obolenja, infektivna respiratorna obolenja, inflamatorna obolenja zucnog trakta, infekcija urinarnog trakta i slicno) kod toplo-krvnih zivotinja ukljucujuci coveka (na primer, pas, macka, govedo, konj, pacov, mis i slicno).
YU37299A 1997-02-07 1998-02-02 Karbapenemsko jedinjenje, njegova primena i njegovo intermedijarno jedinjenje YU37299A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2567197 1997-02-07
JP24890397 1997-09-12

Publications (1)

Publication Number Publication Date
YU37299A true YU37299A (sh) 2002-06-19

Family

ID=26363329

Family Applications (1)

Application Number Title Priority Date Filing Date
YU37299A YU37299A (sh) 1997-02-07 1998-02-02 Karbapenemsko jedinjenje, njegova primena i njegovo intermedijarno jedinjenje

Country Status (24)

Country Link
US (1) US6342494B1 (sh)
EP (1) EP0987267B1 (sh)
KR (1) KR100530478B1 (sh)
CN (1) CN1107067C (sh)
AT (1) ATE239728T1 (sh)
AU (1) AU740327C (sh)
BG (1) BG63974B1 (sh)
BR (1) BR9807187A (sh)
CA (1) CA2280273A1 (sh)
CZ (1) CZ272099A3 (sh)
DE (1) DE69814381T2 (sh)
ES (1) ES2198689T3 (sh)
HK (1) HK1026896A1 (sh)
HU (1) HUP0000952A3 (sh)
ID (1) ID22543A (sh)
NO (1) NO993774L (sh)
NZ (1) NZ337532A (sh)
PL (1) PL335048A1 (sh)
RU (1) RU2178792C2 (sh)
SK (1) SK108099A3 (sh)
TR (1) TR199901887T2 (sh)
TW (1) TW580499B (sh)
WO (1) WO1998034936A1 (sh)
YU (1) YU37299A (sh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400444A3 (en) * 2001-05-21 2007-02-28 Kyoto Pharmaceutical Ind Carbapenem compound, pharmaceutical compositions containing them and their use
WO2003040146A1 (fr) 2001-11-05 2003-05-15 Sumitomo Pharmaceuticals Co., Ltd. Nouveaux composes carbapenem
CA2519794A1 (en) * 2003-04-08 2004-10-21 Sumitomo Pharmaceuticals Co., Ltd. Novel carbapenem compounds
JPWO2006025475A1 (ja) * 2004-09-03 2008-05-08 大日本住友製薬株式会社 新規なカルバペネム化合物
WO2006103999A1 (ja) * 2005-03-25 2006-10-05 Dainippon Sumitomo Pharma Co., Ltd. 新規なカルバペネム化合物
KR100869165B1 (ko) 2007-09-13 2008-11-19 조동옥 메로페넴의 개선된 제조방법
CN101868460A (zh) * 2007-11-23 2010-10-20 国际药品工业株式会社 2-芳基甲基吖丁啶-碳青霉烯-3-羧酸酯衍生物或其盐、其制备方法以及包含上述的药物组合物
CN103504481A (zh) * 2013-10-11 2014-01-15 红塔烟草(集团)有限责任公司 一种带抗菌层烟嘴的电子卷烟

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
FI81576C (fi) * 1984-12-25 1990-11-12 Sankyo Co Foerfarande foer framstaellning av derivat av 6-(1-hydroxietyl)-2-(1,2-disubstituerade-4-pyrrolidinyltio)-2- karbapenem-3-karboxylsyra, vilka aer anvaendbara som laekemedel.
IE60588B1 (en) * 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
AU644008B2 (en) * 1990-08-10 1993-12-02 Sumitomo Pharmaceuticals Company, Limited Beta-lactam compounds, and their production and use
US5712267A (en) * 1991-06-04 1998-01-27 Sankyo Company,. Limited Carbapenem derivatives, their preparation and their use as antibiotics
US5360798A (en) * 1991-07-04 1994-11-01 Shionogi Seiyaku Kabushiki Kaisha Aminooxypyrrolidinylthiocarbapenem compounds
CZ298246B6 (cs) 1995-12-21 2007-08-01 Sankyo Company Limited Deriváty 1-methylkarbapenu, zpusob jejich prípravy a farmaceutické prostredky, které je obsahují
JP3671529B2 (ja) 1996-07-29 2005-07-13 ソニー株式会社 熱転写形記録装置及び記録方法

Also Published As

Publication number Publication date
AU5680698A (en) 1998-08-26
ID22543A (id) 1999-11-04
AU740327B2 (en) 2001-11-01
NO993774L (no) 1999-09-30
DE69814381D1 (de) 2003-06-12
NZ337532A (en) 2001-06-29
US6342494B1 (en) 2002-01-29
KR100530478B1 (ko) 2005-11-23
CA2280273A1 (en) 1998-08-13
AU740327C (en) 2002-05-09
KR20000070809A (ko) 2000-11-25
RU2178792C2 (ru) 2002-01-27
ATE239728T1 (de) 2003-05-15
EP0987267B1 (en) 2003-05-07
CN1107067C (zh) 2003-04-30
CZ272099A3 (cs) 1999-11-17
BG63974B1 (bg) 2003-08-29
BR9807187A (pt) 2000-01-25
SK108099A3 (en) 2000-03-13
NO993774D0 (no) 1999-08-04
HUP0000952A2 (hu) 2000-10-28
HK1026896A1 (en) 2000-12-29
EP0987267A1 (en) 2000-03-22
CN1252072A (zh) 2000-05-03
WO1998034936A1 (fr) 1998-08-13
DE69814381T2 (de) 2003-12-04
BG103699A (en) 2000-06-30
TW580499B (en) 2004-03-21
EP0987267A4 (en) 2000-05-31
PL335048A1 (en) 2000-03-27
TR199901887T2 (xx) 1999-12-21
ES2198689T3 (es) 2004-02-01
HUP0000952A3 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
HK1030373A1 (en) Oxazolidinone derivatives and pharmaceutical compositions.
DE69931809D1 (de) Antibakterielle protonierte oligonukleotide
YU37299A (sh) Karbapenemsko jedinjenje, njegova primena i njegovo intermedijarno jedinjenje
DE69330282D1 (de) Chinolon und acridinon derivate zur behandlung der harninkontinenz
BG105004A (en) Carbapenem derivatives, utilization thereof and intermediate compounds of the same
DE60018186D1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
CA2386685A1 (en) Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases
CA2380455A1 (en) 9a-azalides with antibacterial activity
MXPA03010607A (es) Compuesto de carbapenem.
HUP0003845A2 (hu) Antimikrobiális 8a-azalidok alkalmazása
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
AU5526499A (en) Ingestible compositions comprising antibacterial agents
CA3242451A1 (en) An injectable pharmaceutical composition for the treatment of respiratory diseases in animals
Guibert Overview of clinical experience with pefloxacin in uncomplicated cystitis
TH36001A (th) สารประกอบคาร์บาเพเนม การใช้ประโยชน์ของมัน และสารประกอบมัธยันตร์ของมัน
MXPA02006049A (es) Amonio cuaternario y su uso como agente antitusivo.